Advertisement

 

 

Prospective observational study of carbon-ion radiotherapy for non-squamous cell carcinoma of the head and neck.

Prospective observational study of carbon-ion radiotherapy for non-squamous cell carcinoma of the head and neck.
Author Information (click to view)

Shirai K, Saitoh JI, Musha A, Abe T, Kobayashi D, Takahashi T, Tamaki T, Kawamura H, Takayasu Y, Shino M, Toyoda M, Takahashi K, Hirato J, Yokoo S, Chikamatsu K, Ohno T, Nakano T, ,


Shirai K, Saitoh JI, Musha A, Abe T, Kobayashi D, Takahashi T, Tamaki T, Kawamura H, Takayasu Y, Shino M, Toyoda M, Takahashi K, Hirato J, Yokoo S, Chikamatsu K, Ohno T, Nakano T, , (click to view)

Shirai K, Saitoh JI, Musha A, Abe T, Kobayashi D, Takahashi T, Tamaki T, Kawamura H, Takayasu Y, Shino M, Toyoda M, Takahashi K, Hirato J, Yokoo S, Chikamatsu K, Ohno T, Nakano T, ,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

Cancer science 2017 07 21() doi 10.1111/cas.13325
Abstract

To evaluate the efficacy and safety of carbon-ion radiotherapy for non-squamous cell carcinoma of the head and neck. Thirty-five patients were enrolled in this prospective study. The primary endpoint was the 3-year local control rate, while secondary endpoints included the 3-year overall survival rate and adverse events. Acute and late adverse events were evaluated according to the Common Terminology Criteria for Adverse Events, version 4.0. The median follow-up time for all patients was 39 months. Thirty-two and 3 patients received 64.0 Gy (RBE) and 57.6 Gy (RBE) in 16 fractions, respectively. Adenoid cystic carcinoma was dominant (60%). Four patients had local recurrence and 5 patients died. The 3-year local control and overall survival rates were 93% and 88%. Acute grade 2 to 3 radiation mucositis (65%) and dermatitis (31%) was common, which improved immediately with conservative therapy. Late mucositis of grade 2, grade 3, and grade 4 were observed in 11, 1, and 0 patients. There were no adverse events of grade 5. Carbon-ion radiotherapy achieved excellent local control and overall survival rates for non-squamous cell carcinoma. However, the late mucosal adverse events were not rare, and meticulous treatment planning is required. (UMIN000007886) This article is protected by copyright. All rights reserved.

Submit a Comment

Your email address will not be published. Required fields are marked *

three × 2 =

[ HIDE/SHOW ]